RIPK1 and myocardial infarction: This implies that targeting the FTO/circCacna1c/Hnrnpf/RIPK1 pathway could be a promising approach for mitigating necroptosis-induced loss of cardiomyocytes in ischemic cardiovascular diseases, particularly MI.